

# Bernard H Bochner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7586132/publications.pdf>

Version: 2024-02-01

240  
papers

26,499  
citations

12303

69  
h-index

6630

156  
g-index

255  
all docs

255  
docs citations

255  
times ranked

23264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. <i>European Urology Focus</i> , 2022, 8, 160-164.	1.6	21
2	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. <i>BJU International</i> , 2022, 129, 463-469.	1.3	9
3	Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. <i>European Urology</i> , 2022, 81, 294-304.	0.9	33
4	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
6	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1427-1432.	0.5	8
7	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 431-441.	0.9	5
8	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. <i>Bladder Cancer</i> , 2022, 8, 291-301.	0.2	1
9	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
10	Ureteroenteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot-assisted radical cystectomy. <i>BJU International</i> , 2022, 130, 809-814.	1.3	3
11	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.07.016">https://doi.org/10.1016/j.eururo.2020.07.016</a> . <i>European Urology</i> , 2021, 79, e56-e57.	0.9	0
12	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. <i>Journal of Urology</i> , 2021, 205, 400-406.	0.2	6
13	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4599-4609.	3.2	26
14	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.2	2
15	Management of Common Complications After Radical Cystectomy, Lymph Node Dissection, and Urinary Diversion. , 2021, , 185-203.		0
16	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	2.9	14
17	Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. <i>Urology</i> , 2020, 144, 225-229.	0.5	22
18	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. <i>European Urology</i> , 2020, 77, 1-2.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?. <i>European Urology Focus</i> , 2020, 6, 615-616.	1.6	2
20	A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. <i>Urology</i> , 2020, 135, 57-65.	0.5	37
21	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 406-414.	0.8	60
22	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
23	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	0.9	21
24	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	0.9	30
25	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 306-315.	2.6	97
26	Expeditious Radical Cystectomy in Patients with High-risk Bladder Cancer Remains an Important Part of Patient Care. <i>European Urology Oncology</i> , 2020, 3, 250-251.	2.6	0
27	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	0.9	32
28	Primary urethral cancer: treatment patterns and associated outcomes. <i>BJU International</i> , 2020, 126, 359-366.	1.3	7
29	Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use. <i>Current Opinion in Urology</i> , 2020, 30, 415-420.	0.9	25
30	AUTHOR REPLY. <i>Urology</i> , 2020, 135, 65.	0.5	0
31	Goal-directed <i>versus</i> Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy. <i>Anesthesiology</i> , 2020, 133, 293-303.	1.3	25
32	Utility of Routine Preoperative <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. <i>Journal of Urology</i> , 2020, 204, 254-259.	0.2	19
33	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. <i>Journal of Urology</i> , 2020, 204, 460-465.	0.2	2
34	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. <i>Journal of Urology</i> , 2020, 204, 677-684.	0.2	13
35	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 259-259.	0.2	0
36	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 684-684.	0.2	0

#	ARTICLE	IF	CITATIONS
37	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 51-60.	1.2	31
38	Reply to Siebren Dijkstra and Carl J. Wijkstra's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>Eur Urol</i> 2018;74:465-471. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. <i>European Urology</i> , 2019, 75, e138-e139.	0.9	1
39	A Thoughtful Pause for Spraying Oophorectomy. <i>Urology</i> , 2019, 129, 237.	0.5	0
40	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019, 248, 260-265.	2.1	37
41	The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum. <i>Bladder Cancer</i> , 2019, 5, 13-19.	0.2	6
42	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2401-2407.	1.2	7
43	Leveraging Latent Dirichlet Allocation in processing free-text personal goals among patients undergoing bladder cancer surgery. <i>Quality of Life Research</i> , 2019, 28, 1441-1455.	1.5	34
44	Evolution in technique of robotic intracorporeal continent catheterizable pouch after cystectomy. <i>Urology Video Journal</i> , 2019, 4, 100020.	0.1	2
45	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	2.1	59
46	Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. <i>World Journal of Urology</i> , 2019, 37, 85-93.	1.2	21
47	Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology. <i>Value in Health</i> , 2019, 22, 225-230.	0.1	38
48	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
49	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	3.2	164
50	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239.	0.9	104
51	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 201-204.	1.6	30
52	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. <i>European Urology Focus</i> , 2019, 5, 104-108.	1.6	58
53	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , 2019, 5, 365-368.	1.6	20
54	Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 4458-4464.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. <i>Cancer</i> , 2018, 124, 2507-2514.	2.0	13
56	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. <i>BJU International</i> , 2018, 122, 627-632.	1.3	24
57	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 645-653.	1.2	2
58	Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome. <i>European Urology</i> , 2018, 73, 558-559.	0.9	1
59	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 213-218.	0.9	13
60	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , 2018, 77, 63-69.	1.1	27
61	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	0.9	7
62	Male Neobladder. <i>Urologic Clinics of North America</i> , 2018, 45, 37-48.	0.8	4
63	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	3.2	85
64	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e23-e27.	0.9	19
65	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	29
66	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	0.8	110
67	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , 2018, 122, 121-126.	0.5	5
68	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>European Urology</i> , 2018, 74, 465-471.	0.9	189
69	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT / Over 0.9 372	0.9	372
70	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. <i>World Journal of Urology</i> , 2017, 35, 327-335.	1.2	26
71	Idiographic quality of life assessment before radical cystectomy. <i>Psycho-Oncology</i> , 2017, 26, 206-213.	1.0	8
72	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	3.2	225

#	ARTICLE	IF	CITATIONS
73	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
74	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>Journal of Urology</i> , 2017, 198, 552-559.	0.2	632
75	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <i>Cancer Cytopathology</i> , 2017, 125, 416-426.	1.4	26
76	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 603.e1-603.e5.	0.8	15
77	Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. <i>European Urology</i> , 2017, 71, 299-300.	0.9	2
78	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , 2017, 71, 545-557.	0.9	72
79	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	0.5	52
80	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	0.9	263
81	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). <i>Bladder Cancer</i> , 2017, 3, 113-119.	0.2	13
82	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
83	Title is missing!. , 2017, , .		9
84	Complications of Ileal Conduit Diversion. , 2017, , 63-79.		2
85	Parastomal hernias after radical cystectomy and ileal conduit diversion. <i>Investigative and Clinical Urology</i> , 2016, 57, 240.	1.0	33
86	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. <i>Journal of Urology</i> , 2016, 196, 1014-1020.	0.2	41
87	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723.	2.0	50
88	Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. <i>European Urology Focus</i> , 2016, 2, 441-444.	1.6	8
89	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , 2016, 17, 9.	1.0	28
90	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. <i>European Urology</i> , 2016, 70, 176-187.	0.9	230

#	ARTICLE	IF	CITATIONS
91	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	9.4	143
92	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.2	36
93	Comparison of Perioperative Outcomes for Epidural Versus Intravenous Patient-Controlled Analgesia After Radical Cystectomy. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 239-244.	1.1	25
94	Id Proteins Contribute to Tumor Development and Metastatic Colonization in A Model of Bladder Carcinogenesis. <i>Bladder Cancer</i> , 2015, 1, 159-170.	0.2	2
95	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2015, 67, 1042-1050.	0.9	453
96	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	0.9	122
97	Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation. <i>European Urology</i> , 2015, 67, 350-351.	0.9	3
98	Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , 2015, 67, 363-375.	0.9	158
99	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	0.9	211
100	Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 331.e17-331.e23.	0.8	11
101	Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy. <i>Urologic Clinics of North America</i> , 2015, 42, 189-199.	0.8	7
102	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. <i>Urology</i> , 2015, 85, 596-604.	0.5	30
103	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	0.9	202
104	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. <i>Clinical Imaging</i> , 2015, 39, 94-98.	0.8	17
105	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
106	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	7.7	506
107	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1873-1883.	3.2	63
108	A Randomized Trial of Robot-Assisted Laparoscopic Radical Cystectomy. <i>New England Journal of Medicine</i> , 2014, 371, 389-390.	13.9	114

#	ARTICLE	IF	CITATIONS
109	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	12
110	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.	1.9	69
111	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014, 113, 11-23.	1.3	274
112	Synthetic Lethality in ATM-Deficient <i>RAD50</i> -Mutant Tumors Underlies Outlier Response to Cancer Therapy. <i>Cancer Discovery</i> , 2014, 4, 1014-1021.	7.7	114
113	Risk Factors for the Development of Parastomal Hernia after Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 1708-1713.	0.2	76
114	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2014, 32, 453-459.	1.2	24
115	The mechanism of action of BCG therapy for bladder cancer—a current perspective. <i>Nature Reviews Urology</i> , 2014, 11, 153-162.	1.9	535
116	More on Robot-Assisted Laparoscopic Radical Cystectomy. <i>New England Journal of Medicine</i> , 2014, 371, 1654-1655.	13.9	4
117	Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. <i>Proteomics - Clinical Applications</i> , 2014, 8, 317-326.	0.8	14
118	Adherence to surveillance guidelines after radical cystectomy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 779-784.	0.8	12
119	Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3291-3298.	0.8	37
120	Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. <i>International Urology and Nephrology</i> , 2014, 46, 1699-1705.	0.6	31
121	Editorial Comment. <i>Urology</i> , 2014, 83, 861-862.	0.5	0
122	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 192, 702-707.	0.2	61
123	The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder Funding: Supported by the Sidney Kimmel Center for Prostate and Urologic Cancer and the Michael and Zea Wiener Foundation. Dr Sfakianos is a research fellow in urologic oncology supported by NIH T32-CA82088.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 657-662.	0.8	15
124	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States Funding source: The US Office of Management and Budget (0925-0046).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 637-644.	0.8	46
125	Who should be included in a clinical trial of screening for bladder cancer?. <i>Cancer</i> , 2013, 119, 143-149.	2.0	35
126	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. <i>BJU International</i> , 2013, 111, 589-595.	1.3	24



#	ARTICLE	IF	CITATIONS
127	Oncologic Outcomes Achieved by Radical Cystectomy. <i>European Urology</i> , 2013, 64, 225-226.	0.9	2
128	Urinary Diversion Practice Patterns Among Certifying American Urologists. <i>Journal of Urology</i> , 2013, 189, 1042-1047.	0.2	14
129	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3133-3140.	0.8	282
130	Upper Tract Imaging Surveillance is not Effective in Diagnosing Upper Tract Recurrence in Patients Followed for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2013, 190, 1187-1191.	0.2	38
131	ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate. <i>European Urology</i> , 2013, 63, 81-87.	0.9	24
132	A prospective study of quality of life in patients undergoing pelvic exenteration: Interim results. <i>Gynecologic Oncology</i> , 2013, 128, 191-197.	0.6	44
133	Summary of the 6th annual bladder cancer think tank: New directions in urologic research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 968-973.	0.8	6
134	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. <i>European Urology</i> , 2013, 64, 266-276.	0.9	62
135	Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. <i>BJU International</i> , 2013, 111, E325-30.	1.3	78
136	Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guérin Treatment Failure. <i>Journal of Urology</i> , 2013, 190, 1686-1691.	0.2	40
137	Towards risk stratification in bladder cancer. <i>Nature Reviews Urology</i> , 2013, 10, 374-375.	1.9	0
138	Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?. <i>Current Opinion in Urology</i> , 2013, 23, 449-455.	0.9	6
139	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
140	Technical Advances in Bladder Cancer Patient Care: Progress or Promise?. <i>European Urology</i> , 2012, 62, 814-815.	0.9	3
141	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. <i>Science</i> , 2012, 338, 221-221.	6.0	681
142	Pubovesical Fistula: A Rare Complication After Treatment of Prostate Cancer. <i>Urology</i> , 2012, 80, 446-451.	0.5	53
143	Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1323-1333.	3.2	177
144	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. <i>Molecular Imaging and Biology</i> , 2012, 14, 245-251.	1.3	51

#	ARTICLE	IF	CITATIONS
145	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. <i>BJU International</i> , 2012, 109, 77-82.	1.3	164
146	Lymph Node-Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity. <i>European Urology</i> , 2012, 61, 1025-1030.	0.9	98
147	Pelvic exenteration with curative intent for recurrent uterine malignancies. <i>Gynecologic Oncology</i> , 2012, 124, 42-47.	0.6	63
148	Re: "Pelvic exenteration with curative intent for recurrent uterine malignancies". <i>Gynecologic Oncology</i> , 2012, 126, 312-313.	0.6	0
149	Muscle-Invasive Urothelial Carcinoma: Conventional and Variant Subtypes. , 2012, , 143-163.		0
150	A Plea for a Uniform Surveillance Schedule After Radical Cystectomy. <i>Journal of Urology</i> , 2011, 185, 2091-2096.	0.2	17
151	Bladder cancer imaging. <i>Current Opinion in Urology</i> , 2011, 21, 393-397.	0.9	10
152	Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. <i>BJU International</i> , 2011, 108, E272-E277.	1.3	14
153	The Role of Laparoscopic and Robotic Cystectomy in the Management of Muscle-Invasive Bladder Cancer With Special Emphasis on Cancer Control and Complications. <i>European Urology</i> , 2011, 60, 767-775.	0.9	145
154	The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 10.	1.0	27
155	Somatic mutation of fibroblast growth factor receptor-3 ( <i>FGFR3</i> ) defines a distinct morphological subtype of high-grade urothelial carcinoma. <i>Journal of Pathology</i> , 2011, 224, 270-279.	2.1	73
156	Standardizing the care of invasive bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 454-455.	12.5	3
157	Intravesical Fiducial Marker Placement to Facilitate Image-Guided Radiation Therapy for Patients With Muscle-Invasive Bladder Cancer. <i>UroToday International Journal</i> , 2011, 04, .	0.1	0
158	The effect of age on bladder cancer incidence, prognosis and therapy. <i>Aging Health</i> , 2010, 6, 649-659.	0.3	7
159	Re: Outcome After Radical Cystectomy with Limited or Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2010, 57, 175.	0.9	2
160	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. <i>European Urology</i> , 2010, 58, 374-383.	0.9	52
161	Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. <i>European Urology</i> , 2010, 58, 581-587.	0.9	227
162	The Effect of Tumor Location on Prognosis in Patients Treated with Radical Nephroureterectomy at Memorial Sloan-Kettering Cancer Center. <i>European Urology</i> , 2010, 58, 574-580.	0.9	159

#	ARTICLE	IF	CITATIONS
163	Comparison Between Laparoscopic and Open Radical Nephroureterectomy in a Contemporary Group of Patients: Are Recurrence and Disease-Specific Survival Associated with Surgical Technique?. <i>European Urology</i> , 2010, 58, 645-651.	0.9	98
164	The effect of age and gender on bladder cancer: a critical review of the literature. <i>BJU International</i> , 2010, 105, 300-308.	1.3	281
165	Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. <i>BJU International</i> , 2010, 106, 1502-1507.	1.3	11
166	Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. <i>Journal of Urology</i> , 2010, 184, 464-469.	0.2	35
167	Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series. <i>Journal of Urology</i> , 2010, 184, 74-80.	0.2	48
168	Oncological Outcomes After Radical Cystectomy for Bladder Cancer: Open Versus Minimally Invasive Approaches. <i>Journal of Urology</i> , 2010, 183, 862-870.	0.2	74
169	Overview of SUO Winter 2008 proceedings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 67-68.	0.8	0
170	Impact of Previous Radiotherapy for Prostate Cancer on Clinical Outcomes of Patients With Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 1751-1756.	0.2	26
171	Does DW-MRI have a role in the evaluation of hematuria?. <i>Nature Reviews Urology</i> , 2009, 6, 469-470.	1.9	2
172	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. <i>Journal of Clinical Oncology</i> , 2009, 27, 5680-5684.	0.8	56
173	Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience. <i>European Urology</i> , 2009, 55, 177-186.	0.9	227
174	Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. <i>European Urology</i> , 2009, 55, 164-176.	0.9	1,145
175	Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. <i>European Urology</i> , 2009, 56, 903-910.	0.9	111
176	Clinical benefits of a multivariate prediction model for bladder cancer. <i>Cancer</i> , 2009, 115, 5460-5469.	2.0	32
177	Optimal timing of radical cystectomy for patients with T1 bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 329-331.	0.8	16
178	Ureteroileocecal Appendicostomy Based Urinary Reservoir in Irradiated and Nonirradiated Patients. <i>Journal of Urology</i> , 2009, 182, 2376-2381.	0.2	11
179	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI. , 2009, , 67-77.		0
180	Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. <i>Cancer</i> , 2008, 112, 2384-2392.	2.0	281

#	ARTICLE	IF	CITATIONS
181	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2008, 113, 2471-2477.	2.0	239
182	Risk Assessment of Prostatic Pathology in Patients Undergoing Radical Cystoprostatectomy. <i>European Urology</i> , 2008, 53, 370-375.	0.9	90
183	Longitudinal Risk of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer and the Potential Implications for Long-Term Surveillance. <i>Journal of Urology</i> , 2008, 179, 96-100.	0.2	73
184	Gene therapy in bladder cancer. <i>Current Opinion in Urology</i> , 2008, 18, 519-523.	0.9	15
185	Bladder cancer: can imaging change patient management?. <i>Current Opinion in Urology</i> , 2008, 18, 98-104.	0.9	36
186	How prevalent is neobladder emptying failure, and how can it be treated?. <i>Nature Reviews Urology</i> , 2007, 4, 364-365.	1.4	0
187	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. <i>Clinical Cancer Research</i> , 2007, 13, 4511-4518.	3.2	29
188	Adenoviral Receptor Expression of Normal Bladder and Transitional Cell Carcinoma of the Bladder. <i>Urologia Internationalis</i> , 2007, 78, 160-166.	0.6	24
189	Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract. <i>Urology</i> , 2007, 69, 255-259.	0.5	79
190	The use and abuse of data: Nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 333-337.	0.8	9
191	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. <i>American Journal of Pathology</i> , 2007, 171, 1650-1658.	1.9	30
192	Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 1283-1286.	0.2	146
193	Urachal Carcinoma: Contemporary Surgical Outcomes. <i>Journal of Urology</i> , 2007, 178, 74-78.	0.2	137
194	Prognostic significance of p27Kip1 expression in bladder cancer. <i>BJU International</i> , 2007, 100, 259-263.	1.3	33
195	Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2007, 14, 26-32.	0.5	57
196	Detection and Management of Isolated Lymph Node Recurrence in Patients with PSA Relapse. <i>European Urology</i> , 2007, 52, 310-312.	0.9	2
197	Radical Cystectomy and Lymphadenectomy for Invasive Bladder Cancer: Towards the Evolution of an Optimal Surgical Standard. <i>Seminars in Oncology</i> , 2007, 34, 110-121.	0.8	19
198	Association Between Urinary Cytology and Pathology for Nontransitional Cell Malignancies of the Urinary Tract. <i>Journal of Urology</i> , 2006, 175, 2038-2041.	0.2	10

#	ARTICLE	IF	CITATIONS
199	Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients. <i>Journal of Urology</i> , 2006, 176, 482-485.	0.2	52
200	Natural History of Positive Urinary Cytology After Radical Cystectomy. <i>Journal of Urology</i> , 2006, 176, 2000-2005.	0.2	25
201	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. <i>Journal of Clinical Oncology</i> , 2006, 24, 5519-5527.	0.8	88
202	Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 474-475.	4.3	4
203	Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1019-1026.	2.3	1
204	Is lymphovascular invasion an important prognostic factor in patients with bladder cancer?. <i>Nature Reviews Urology</i> , 2006, 3, 188-189.	1.4	0
205	Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. <i>BJU International</i> , 2006, 98, 59-62.	1.3	47
206	Use of nomograms as predictive tools in bladder cancer. <i>World Journal of Urology</i> , 2006, 24, 489-498.	1.2	13
207	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. <i>Cancer</i> , 2006, 107, 506-513.	2.0	360
208	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. <i>Cancer</i> , 2006, 107, 2167-2172.	2.0	69
209	Standardization of pelvic lymphadenectomy performed at radical cystectomy. <i>Cancer</i> , 2006, 107, 2368-2374.	2.0	215
210	Multimodal therapy for urologic cancers. <i>Nature Reviews Urology</i> , 2006, 3, 453-453.	1.4	1
211	Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3967-3972.	0.8	419
212	Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin-Refractory Transitional Cell Carcinoma of the Bladder. <i>Journal of Clinical Oncology</i> , 2006, 24, 2729-2734.	0.8	160
213	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. <i>Current Opinion in Urology</i> , 2005, 15, 315-319.	0.9	11
214	Morbidity of resectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 99, 608-614.	0.6	148
215	DOES BODY MASS INDEX AFFECT SURVIVAL OF PATIENTS UNDERGOING RADICAL OR PARTIAL CYSTECTOMY FOR BLADDER CANCER?. <i>Journal of Urology</i> , 2005, 173, 1513-1517.	0.2	62
216	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 2005, 174, 741-746.	0.2	30

#	ARTICLE	IF	CITATIONS
217	Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin. <i>Clinical Cancer Research</i> , 2004, 10, 1835-1842.	3.2	32
218	Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 7457-7465.	3.2	202
219	Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. <i>Gynecologic Oncology</i> , 2004, 94, 140-146.	0.6	12
220	PARTIAL CYSTECTOMY: A CONTEMPORARY REVIEW OF THE MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERIENCE AND RECOMMENDATIONS FOR PATIENT SELECTION. <i>Journal of Urology</i> , 2004, 172, 878-881.	0.2	151
221	PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPING. <i>Journal of Urology</i> , 2004, 172, 1286-1290.	0.2	193
222	BLADDER CANCER AS A PROGNOSTIC FACTOR FOR UPPER TRACT TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 2004, 172, 2177-2181.	0.2	89
223	Importance of lymph node dissection in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 197.	0.8	0
224	274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2004, 171, 72-72.	0.2	9
225	Follow-up strategies and management of recurrence in urologic oncology bladder cancer:. <i>Urologic Clinics of North America</i> , 2003, 30, 777-789.	0.8	61
226	Detection and Quantitative Analysis of Early Stage Orthotopic Murine Bladder Tumor Using In Vivo Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2003, 170, 1375-1378.	0.2	32
227	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. <i>Journal of Urology</i> , 2003, 169, 177-181.	0.2	97
228	Umbilical Endometriosis. <i>Journal of Urology</i> , 2003, 170, 2388-2389.	0.2	12
229	Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. <i>Journal of Urology</i> , 2003, 169, 177-81.	0.2	28
230	International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2002, 20, 3206-3212.	0.8	203
231	Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector. <i>Journal of Virology</i> , 2002, 76, 12783-12791.	1.5	51
232	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2002, 167, 1295-1298.	0.2	544
233	Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. <i>Journal of Urology</i> , 2002, 167, 1295-8.	0.2	133
234	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. <i>Journal of Urology</i> , 2001, 166, 2295-2296.	0.2	232

#	ARTICLE	IF	CITATIONS
235	NOREPINEPHRINE PRODUCING RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 603-603.	0.2	0
236	Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 666-675.	0.8	3,157
237	Development of lentiviral vectors for antiangiogenic gene delivery. <i>Cancer Gene Therapy</i> , 2001, 8, 879-889.	2.2	58
238	AN ALTERNATIVE URETEROILEAL REIMPLANTATION USED IN AUGMENTATION CYSTOPLASTY FOR NEUROGENIC BLADDER WITH BILATERAL VESICoureTERAL REFLUX. <i>Journal of Urology</i> , 1998, 160, 1416-1417.	0.2	2
239	SALVAGE RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION FOLLOWING RADIATION FAILURE. <i>Journal of Urology</i> , 1998, 160, 29-33.	0.2	88
240	THE T POUCH: AN ORTHOTOPIC ILEAL NEOBLADDER INCORPORATING A SEROSAL LINED ILEAL ANTIREFLUX TECHNIQUE. <i>Journal of Urology</i> , 1998, 159, 1836-1842.	0.2	133